13838-16-9

ENFLURANE(13838-16-9) (Ethrane, 2-chloro-1,1,2-trifluoroethyldifluoromethyl ether) is a nonflammable halogenated hydrocarbon that exists as a clear, colorless, odorless to sweet, volatile liquid at ordinary temperature and pressure. Bp: 56.8°C. Density 1.50 g cm-3 at room temperature. Used as an anesthetic.

The material ENFLURANE is incompatible with the following oxidizing materials, peroxides, combustible materials. Although nonflammable, a fire may cause enflurane to decompose to toxic compounds including phosgene, hydrogen chloride, and hydrogen fluoride. Decomposes slowly in the light.

Volatile with anesthetic properties, but nonflammable. Cardiac and central nervous system impairment. Questionable carcinogen.

FDA-proprietary drug, used as an anesthetic (gas). Axphyxiant

If this chemical gets into the eyes, remove any contact lenses at once and irrigate immediately for at least 15 minutes, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts the skin, remove contaminated clothing and wash immediately with soap and water. Seek medical attention immediately. If this chemical has been inhaled, remove from exposure, begin rescue breathing (using universal precautionsincluding resuscitation mask) if breathing has stopped and CPR if heart action has stopped. Transfer promptly to a medical facility. When this chemical has been swallowed, get medical attention. Give large quantities of water and induce vomiting. Do not make an unconscious person vomit.

UN1851 Medicine, liquid, toxic, n.o.s., Hazard Class: 6.1; Labels: 6.1-Poisonous materials. Cylinders must be transported in a secure upright position, in a wellventilated truck. Protect cylinder and labels from physical damage. The owner of the compressed gas cylinder is the only entity allowed by federal law (49CFR) to transport and refill them. It is a violation of transportation regulations to refill compressed gas cylinders without the express written permission of the owner.

Incompatible with oxidizers (chlorates, nitrates, peroxides, permanganates, perchlorates, chlorine, bromine, fluorine, etc.); contact may cause fires or explosions. Keep away from alkaline materials, strong bases, strong acids, oxoacids, and epoxides. Decomposes on heating, forming toxic and corrosive fumes of hydrogen chloride, hydrogen fluoride, and phosgene. Decomposes in strong sunlight

Enflurane is a clear, colorless liquid with amild, sweet odor, which easily turns into a nonflammablegas. Molecular weight = 184.50; Specific gravity(H2O:1) = 1.52; Boiling point = 56.7 ℃; Vaporpressure 5 175 mmHg; Relative vapor density (air 5 1)=1.92. Hazard Identification (based on NFPA-704 M RatingSystem): Health 2, Flammability 1, Reactivity 0. Veryslightly soluble in water

Clear, colorless liquid; mild, sweet odor. Soluble in organic solvents; slightly soluble in water.

Enflurane is a clear, colorless liquid that easily turns into a nonflammable gas. Mild, sweet odor

The halogenated methyl ethyl ether enflurane is a geometric isomer of isoflurane and boasts similar properties. It is no longer in use in modern clinical practice largely because of some unfavourable adverse effects. Enflurane has been associated with: tonic–clonic muscle activity; epileptiform EEG changes; sensitisation of the myocardium to catecholamines causing dysrhythmias; and hepatotoxicity as a result of its significant liver metabolism.

Return refillable compressed gas cylinders to supplier

Ethrane,Ohio Medical,US,1972

ChEBI: An ether in which the oxygen atom is connected to 2-chloro-1,1,2-trifluoroethyl and difluoromethyl groups.

Preparation of the Intermediate CHCl2OCF2CHFCl: To a 3-necked roundbottomed flask fitted with a Dry Ice condenser, a fritted glass gas inlet tube, a thermometer and a stirrer, was charged 1,180 grams (8 mols) of CH3OCF2CHFCl.After flushing the system with nitrogen, chlorine gas was added via the inlet tube while the reaction was stirred and illuminated with a 300 watt incandescent lamp. The chlorination was rapid and exothermic and the reactor was cooled to hold the temperature between 30° and 35°C. The effluent gases were led from the top of the condenser to a water scrubber which was titrated at intervals with standard base. When a total of 1.45 mols of HCl per mol of ether was titrated the reaction was stopped. The crude product obtained weighed 1,566 grams which corresponded to the addition of 1.41 mols of chlorine per mol of the starting ether. The product was flash distilled to yield 1,480 grams of product which had the following composition as determined by vapor phase chromatography: 45.3% CH2ClOCF2CHFCl; 50.5% CHCl2OCF2CHFCl, plus a small amount of CH2ClOCF2CFCl2; 1.8% CHCl2OCF2CFCl2 and 2.1% CCl3OCF2CHFCl.
Fractional distillation of this mixture using a 5 x 120 cm column packed with ?" Penn State packing yielded 670 grams of product containing 95% CH2ClOCF2CHFCl and 5% CHCl2OCF2CHFCl; BP 55° to 60°C at 100 mm, nD20 = 1.3748 to 1.3795; and 670 grams of CHCl2OCF2CHFCl (95% pure, containing 5% CH2ClOCF2CFCl2); BP 60°C at 100 mm, nD20 = 1.3870 to 1.3875. The still bottoms were comprised mostly of CCl3OCF2CHFCl and CHCl2OCF2CFCl2.
Preparation of CHF2OCF2CHFCl: To a mixture of 2,172 grams (10 mols) CHCl2OCF2CHFCl prepared as described above (containing approximately 5% CH2ClOCF2CFCl2) and 40 grams (2% by weight) SbCl5 was added anhydrous hydrogen fluoride while the temperature was maintained at 0-5°C. The reaction was carried out in a 3-necked stainless steel flask fitted with a stainless steel stirrer, a thermocouple well and a copper Dry Ice condenser.
The amount of hydrogen fluoride added was measured by titration of the HCl given off. At the end of the reaction (total HCl evolved: 1.98 mols per mol of starting ether) the mixture was poured into water and the organic layer (1,803 grams, nD20 = 1.3080) recovered. The crude product was flash distilled in a 60 x 2 cm column packed with ?" Penn State packing giving 1,594 grams of substantially pure CHF2OCF2CHFCl, BP 56° to 57°C. By further distillation 1,450 grams of the pure ether were obtained, BP 56.5°C, nD20 = 1.3030 as described in each of the patents cited as references.

Anesthetic

Enflurane (Ethrane) depresses myocardial contractility and lowers systemic vascular resistance. In contrast to halothane, it does not block sympathetic reflexes, and therefore, its administration results in tachycardia. However, the increased heart rate is not sufficient to oppose enflurane’s other cardiovascular actions, so cardiac output and blood pressure fall. In addition, enflurane sensitizes the myocardium to catecholamine-induced arrhythmias, although to a lesser extent than with halothane. Enflurane depresses respiration through mechanisms similar to halothane’s and requires that the patient’s ventilation be assisted.
Neuromuscular transmission is depressed by enflurane, resulting in some skeletal muscle paralysis.Although muscle relaxation is inadequate for many surgical procedures, the anesthetic enhances the action of neuromuscular blocking agents, thereby lowering the dose of the paralytic agent needed and minimizing side effects.
Deep anesthesia with enflurane is associated with the appearance of seizurelike electroencephalographic (EEG) changes. Occasionally frank tonic–clonic seizures are observed. Consequently, other inhalational agents are usually given to patients with preexisting seizure disorders.
Another concern associated with the use of enflurane is its biotransformation, which leads to increased plasma fluoride. Following lengthy procedures in healthy patients, fluoride may reach levels that result in a mild reduction in renal concentrating ability.Thus, enflurane should be used cautiously in patients with clinically significant renal disease.

The acute toxicity of ethrane by inhalation,ingestion, or intraperitoneal or subcutaneousapplications in rodents was found tobe low to very low at concentrationsof <1000 ppm in air or dosages below1000 mg/kg. In humans it causes anesthesiaat 1.5–2% concentrations (by volume of air).Exposure to concentrations above this levelcan be dangerous. The target organs arethe central nervous system, cardiovascularsystem, kidney, and bladder. The symptomsare anesthesia, respiratory depression, andseizure. Hypotension can occur due toits action on the cardiovascular system.Exposure to a 1% concentration in air for6 hours caused anuria in humans
LC50 value, inhalation (mice): 8100 ppm/3 h
LD50 value, oral (mice): 5000 mg/kg
The pure liquid can cause mild to moder ate irritation of the eyes.
Inhalation of ethrane vapors produced teratogenic effects in mice and rats. Theseeffects pertained to specific developmen tal abnormalities in the urogenital, mus culoskeletal, and central nervous systems.These reproductive effects, however, weremanifested at high exposure levels in therange of LC50 concentrations.
Under the conditions of its use, the con centrations of ethrane in air should be toolow to produce any adverse health effects onhumans. However, it should be borne in mindthat this compound is highly volatile [vaporpressure 175 torr at 20°C (68°F)] and its con centration in air can go up from a spill orimproper handling in confined space.
Inhalation of its vapors resulted in lungand liver tumors in mice. There is no evi dence of its carcinogenic actions in humans.

Noncombustible liquid; flash point >94°C (200°F); low reactivity. Pressure buildup in a closed bottle may occur at elevated temper atures.

Enflurane was introduced into medical practice in the United States in 1973 and is a clear, colorless, nonflammable general liquid with a mild, sweet odor. Although relatively stable chemically, enflurane does not attack aluminum, copper, iron, or brass and is soluble in rubber (partition coefficient = 74), which can prolong induction/recovery times, as seen with halothane.Enflurane has an intermediate solubility in blood and significant potency. Most of its pharmacological properties are similar to those of halothane, although there may be slightly less nausea, vomiting, arrhythmias, and postoperative shivering than observed with halothane. High concentrations of enflurane, however, are more likely to produce convulsions and circulatory depression. Enflurane also relaxes the uterus and, thus, should not be used as an anesthetic during labor. Metabolism via CYP2E1 accounts for 2% of an inhaled dose and includes transformation to the fluoride ion and fluoromethoxydifluoroacetic acid. During recovery, enflurane leaves the fatty tissues rapidly and, therefore, is not available for a prolonged period of time for significant metabolism to proceed.

Enflurane is prepared by dichlorination of the methyl group of 1-chloro-1,2,2-trifluoro-2- methoxyethane and replacement of these two chlorine atoms by fluorine , :

Store at -20°C